Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar Kvedarna (99.68) Submitted: 10/29/2015 10:58:03 AM : Outperform Start Price: $0.68 SNTA Score: -41.12

Year ender

Recs

0
Member Avatar DeathStock (99.28) Submitted: 10/21/2015 2:51:30 PM : Outperform Start Price: $0.56 SNTA Score: -31.64

An Incoming Bounce should be expected.

Recs

0
Member Avatar joienpaix (< 20) Submitted: 3/18/2015 6:22:12 PM : Outperform Start Price: $2.36 SNTA Score: -81.10

2016 Q2

Recs

0
Member Avatar pchop123 (80.99) Submitted: 7/18/2014 6:41:03 PM : Outperform Start Price: $4.11 SNTA Score: -94.49

watch their Ph III Study

Recs

0
Member Avatar swingtrader858 (< 20) Submitted: 5/12/2014 8:01:58 PM : Outperform Start Price: $4.23 SNTA Score: -102.56

HUGE insider purchases. A great sign for a biopharm or biotech company. Buying in the $4's provides a great risk/reward ratio, as so much support plus insider purchases at these levels. Target $6 by end of 2014.

Recs

0
Member Avatar vutilolo (< 20) Submitted: 5/8/2014 10:21:24 AM : Outperform Start Price: $4.20 SNTA Score: -99.33

We are at all-time lows here. With SNTA selling stock @ 4.01 to a large holder, we all have the chance here to pick up this stock @ "employee pricing". Long term win!

Recs

0
Member Avatar OKwarrior (22.11) Submitted: 4/20/2014 12:29:51 PM : Outperform Start Price: $3.99 SNTA Score: -100.14

This is a roller coaster ride, high risk, higher (I hope) returns. They are burning through cash, but unlike a lot of zombie biotechs, they do have a chance of hitting the big one.

I am green thumbing it now only d/t the charts which suggest it is near the bottom of a trading range. Of course Custer thought it was just a couple of scouts on the ridge at Little Big Horn.

Recs

0
Member Avatar CountDaBean (71.90) Submitted: 2/16/2014 3:07:05 AM : Outperform Start Price: $6.32 SNTA Score: -105.07

New drug in trials. Expect shares to jump to 10.00 a share if trials are successful

Recs

0
Member Avatar jpokergman (< 20) Submitted: 11/18/2013 5:39:35 PM : Outperform Start Price: $4.98 SNTA Score: -106.43

big insider buy....that's why.

Recs

0
Member Avatar ssanaka (< 20) Submitted: 6/16/2013 10:19:00 AM : Outperform Start Price: $4.09 SNTA Score: -115.19

possible blockbuster lung cancer drug in the pipeline

Recs

0
Member Avatar frankyz669 (< 20) Submitted: 9/3/2010 10:23:24 AM : Outperform Start Price: $2.92 SNTA Score: -172.76

Magic Formula - though speculative. I think it made the MF list because of huge cash infusion from selling its position with another partner.

Recs

1
Member Avatar cibient (< 20) Submitted: 2/4/2010 1:14:38 PM : Outperform Start Price: $4.08 SNTA Score: -181.49

Surge of insider buying inspires confidence. While this means nothing if the drug ultimately doesn't fly, or heavy dilution tramples existing shareholders, the company has a good balance sheet due to the recent capital raise.

Recs

0
Member Avatar aulden1954 (< 20) Submitted: 1/15/2010 7:51:08 PM : Outperform Start Price: $4.84 SNTA Score: -172.28

Their product base has started rough with the cancer drug but, they have good products in the pipe line that is giving some positive light on the companies pipe line of products.

I like my chances because the company has many other products they are bringing to market. If they only bring one to market and get bough out they have become a success haven't they.

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 1/13/2010 7:37:20 AM : Outperform Start Price: $4.63 SNTA Score: -171.39

Insiders just (Jan.) purchased 5+% of the company at this price. Insiders do not buy millions of their own biotech company without good reason.

Recs

0
Member Avatar dgu004 (95.85) Submitted: 12/22/2009 5:00:32 AM : Underperform Start Price: $6.50 SNTA Score: +177.64

Went too high before the trail is successful. Red ink will show again for the quarters to come.

Recs

0
Member Avatar TuffPicks (< 20) Submitted: 9/22/2009 12:17:50 PM : Outperform Start Price: $3.15 SNTA Score: -178.64

wallstreet buy list

Recs

0
Member Avatar biovestor (< 20) Submitted: 6/28/2008 6:22:16 AM : Outperform Start Price: $5.93 SNTA Score: -158.68

A cancer biotech stock with a promising Phase 3 candidate for metastatic melanoma (elesclomol) along with a full early stage pipeline.

Recs

0
Member Avatar glfraley (99.60) Submitted: 1/29/2008 3:14:44 PM : Outperform Start Price: $7.15 SNTA Score: -151.35

Just won orphan status for their already fast tracked melanoma drug. should be interesting to see how this develops.

Recs

0
Member Avatar ivhadit (< 20) Submitted: 1/19/2008 6:41:50 PM : Outperform Start Price: $6.50 SNTA Score: -161.86

IF THIS HITS WATCH OUT

Recs

0
Member Avatar Dtrifan (< 20) Submitted: 11/13/2007 9:49:01 PM : Outperform Start Price: $8.37 SNTA Score: -139.19

Cancer drug market at a low price

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners